Highest-materiality recent filing
Jury found for Cytek on 3 of 4 asserted claims (noninfringement and invalidity).
Cytek Biosciences Q2 2026 revenue $48.1M (+6% YoY); net loss widens to $12.2M from $5.6M
Total revenue $48.1M, up 6% YoY; GAAP gross margin improved to 59% from 52%.
Cytek Biosciences enters severance and consulting agreements with former CLO Valerie Barnett
Valerie Barnett's CLO role terminated June 29, 2026; severance lump sum of $365,775.12 plus COBRA through April 30, 2027.
Cytek Biosciences CLO Valerie Barnett to depart on June 29, 2026
CLO and Corporate Secretary Valerie Barnett to leave Cytek effective June 29, 2026.
Cytek stockholders elect three Class II directors, approve advisory pay and auditor ratification
Three Class II directors elected: Vera Imper (64.8M for, 20.7M withheld), Glenn P. Muir (79.6M for), Ming Yan (76.7M for).
Cytek Biosciences SVP Global Sales Philippe Busque resigns effective June 5
Philippe Busque, Ph.D., SVP Global Sales and Services, resigned effective June 5, 2026.
Cytek Q1 revenue $44.1M (+6% YoY); net loss widens to $18.9M; reaffirms FY guidance
Total revenue $44.1M (+6% YoY); service revenue $15.4M (+15%).
Cytek Q4 revenue $62.1M (+8% YoY); net loss $44.1M on $38.1M deferred tax valuation allowance
Full-year 2025 revenue $201.5M (+1% YoY); Q4 set record quarterly revenue.
Cytek sees Q4 rev $62M (+8% YoY); FY2025 rev ~$201M
Preliminary Q4 2025 revenue of ~$62M, up 8% YoY and 19% QoQ.
Cytek Q3 2025 net loss $5.5M; adjusted EBITDA $2.5M; revenue +2% to $52.3M
Total revenue $52.3M, +2% YoY; installed base 3,456 instruments (+161 units in Q3).
Cytek Q2 2025 revenue $45.6M (-2% YoY); narrows 2025 guidance to $196-205M
Revenue $45.6M, down 2% YoY; net loss $5.6M vs $10.4M loss in Q2 2024.
Cytek director nominee Deborah Neff fails election; other proposals pass
Deborah Neff received 33.8M votes for vs. 48.2M withheld, failing to be elected as Class I director.
Cytek Q1 revenue down 7.6% to $41.5M; net loss widens; FY2025 guidance reduced
Revenue $41.5M (-7.6% YoY); gross margin 49% vs 51%; net loss $11.4M vs $6.2M loss prior year.
Cytek Biosciences Q4 rev $57.5M (-1.3%); FY24 net loss $6.0M; guides FY25 rev $204-212M
Full year 2024 revenue $200.5M (+3.9% YoY); Q4 revenue $57.5M (-1.3% YoY, +1.4% constant currency).
Cytek Biosciences expects FY2024 revenue $200-201M, 4% growth; Q4 rev up 11-13% QoQ
Full-year 2024 revenue expected $200-201M, up 4% from $193M in 2023; ~$1M negative FX impact.
Cytek Q3 revenue $51.5M (+7% YoY); net income $0.9M vs loss year ago
Total revenue $51.5M, up 7% vs Q3 2023; year-to-date revenue $143.0M, up 6%.
Cytek Biosciences COO Paul Christopher Williams resigns effective Sept 27, 2024
COO Paul Christopher Williams resigned on Sept 9, 2024, effective Sept 27, 2024, to pursue another career opportunity.
Cytek Q2 revenue $46.6M, -6% YoY; net loss widens to $10.4M
Revenue $46.6M (-6% YoY, +4% QoQ); GAAP gross margin 55% (adjusted 58%).
Cytek Biosciences 2024 annual meeting results: all proposals approved by shareholders
Elected Wenbin Jiang and Michael Holder as Class III directors with 64.2M and 70.3M votes for, respectively.
Cytek Q1 revenue $44.9M (+21% YoY); organic revenue up 11%; reaffirms 2024 guidance
Total revenue $44.9M, +21% YoY; organic revenue (ex-Luminex) $37.3M, +11%.
Cytek Biosciences appoints William McCombe as CFO, reaffirms 2024 revenue guidance
Patrik Jeanmonod steps down as CFO to become Head of Corporate Development Analytics, effective March 17, 2024.
Total revenue Q4 $58.6M (+21% YoY); organic $48.8M (+1%); full year $193.4M (+18%).
Cytek Biosciences amends severance plan; CEO gets 12-month base, 24-month on change of control
Compensation Committee approved Second Amended and Restated Severance Benefit Plan effective Feb 20, 2024.
Cytek Biosciences prelim FY2023 revenue near high end of $188M-$192M guidance
Preliminary full-year 2023 revenue expected near high end of prior guidance range of $188M-$192M.
Cytek Biosciences posts updated corporate presentation, no material new info disclosed
Filing references updated corporate presentation made available on company website.
Cytek Biosciences reports Q3 2023 earnings; no financial details in furnished transcript
Company announced preliminary financial results for quarter ended September 30, 2023.
Cytek Q3 revenue $48M (+19%), organic growth 2%; net loss $6.5M; FY guidance $188-192M
Total revenue $48.0M (+19% YoY); organic revenue $41.2M (+2%); acquired Luminex contributed $6.8M.
Cytek Q2 revenue up 24% to $49.7M; net loss widens to $4.4M
Revenue $49.7M (+24% YoY); organic revenue $41.5M (+3%) excl. $8.2M from Luminex acquisition.
Cytek Biosciences shareholders elect three Class II directors and approve say-on-pay
All three director nominees (Jack Ball, Vera Imper, Ming Yan) elected with 55.9M–56.9M votes for; broker non-votes 25.6M.
Cytek acquired flow cytometry business with $43.1M revenue, $4.4M loss in 2022
Purchase price was $46.5M less $1.6M working capital adjustments and transaction fees.
Total revenue $37.1M, up 6% YoY; constant-currency revenue $38.1M (+9%).
Cytek Biosciences completes $46.5M acquisition of Luminex flow cytometry assets
Closed acquisition of Luminex's flow cytometry and imaging business (Amnis, CellStream, Guava, Muse brands) on Feb 28, 2023.
Cytek Q4 revenue $48.3M (+24% YoY); guides FY2023 $225-235M (+37-43%)
Full-year 2022 revenue $164.0M, up 28% YoY (34% constant currency); net income $2.5M.
Cytek Biosciences to acquire flow cytometry & imaging assets from Luminex for $46.5M
Purchase price ~$46.5M cash; deal expected to close within 30 days; includes >7,000 installed instruments.
Cytek Q3 revenue $40.5M (+18% YoY); net income $1.6M; guides FY near high end of $160-168M
Revenue $40.5M (+18% YoY); gross margin improved to 66.4% from 61.9%.
Cytek Biosciences appoints Chris Williams as COO, effective Oct. 31, 2022
Chris Williams appointed COO, reporting to CEO Wenbin Jiang; focused on scaling global operations.
Cytek Q2 revenue $40.2M (+32% YoY); net loss of $0.7M vs prior-year net income $2.7M
Revenue $40.2M, up 32% YoY; gross profit $24.6M (61% margin) vs $19.7M (65% margin) prior year.
Deborah Neff and Don Hardison elected as Class I directors with ~88.7M and ~88.7M votes for, respectively.
Cytek Q1 revenue up 44% to $35.1M; raises FY2022 revenue guidance
Revenue $35.1M, +44% YoY; installed base grew to 1,226 instruments with 116 new placements.
Cytek sets 2022 executive comp: salaries, bonuses, equity grants
CEO Wenbin Jiang: 2022 base salary $545,000, target bonus 80% of base.
Cytek Q4 revenue $38.9M (+27% YoY); FY2021 revenue $128M (+38%); guides FY2022 $160-168M
Q4 2021 revenue $38.9M (+27% YoY); FY2021 revenue $128.0M (+38% YoY).
Cytek Biosciences appoints Dr. Vera Imper to board of directors
Board expanded from six to seven members; Dr. Imper appointed as Class II director effective Dec 31, 2021.
Cytek Q3 revenue $34.4M (+37% YoY); net income $1.6M down from $6.5M
Total revenue $34.4M, up 37% YoY; gross margin 62% (non-GAAP 64%).
Cytek Biosciences Q2 revenue $30.4M (+59% YoY); operating income turns positive at $3.8M
Revenue $30.4M, +59% YoY; gross margin improved to 65% from 43%.
Cytek enters non-exclusive laser supply agreement with Coherent NA
Supply Agreement with Coherent NA for laser products; no minimum purchase obligation.
Cytek Biosciences closes IPO of 14.56M shares at $17.00 per share, raising $200M gross
Closed IPO on July 27, 2021; issued 14,564,635 shares at $17.00 per share.
On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc. (the “Company”), effective as of June 5, 2026, to pursue another career opportunity.
On September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of Cytek Biosciences, Inc. (the “Company”), effective as of September 27, 2024, to pursue another career opportunity.
Effective as of March 17, 2024, Patrik Jeanmonod stepped down from his position as the Chief Financial Officer of Cytek Biosciences, Inc. (the “Company”) to serve as the Company’s Head of Corporate Development Analytics.
On March 19, 2024, the Board of Directors of the Company announced the appointment of William (“Bill”) McCombe as the Chief Financial Officer of the Company, effective March 18, 2024.
the Board of Directors (the “Board”) of Cytek Biosciences, Inc. (the “Company”) announced the appointment of Chris Williams as the Company’s Chief Operating Officer, effective October 31, 2022.
the Board unanimously voted to (i) increase the number of authorized directors on the Board from six to seven and (ii) appoint Dr. Vera Imper to serve as a Class II director of the Company, effective December 31, 2021
Max materiality 0.85 · Median 0.65 · Most common event earnings